JMP Securities Increases Deciphera Pharmaceuticals (DCPH) Price Target to $65.00

Deciphera Pharmaceuticals (NASDAQ:DCPH) had its price objective increased by JMP Securities to $65.00 in a note issued to investors on Tuesday, The Fly reports. The brokerage presently has an “outperform” rating on the stock. JMP Securities’ price target would indicate a potential upside of 45.32% from the stock’s current price.

Several other equities analysts also recently weighed in on the company. B. Riley downgraded Deciphera Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $43.00 target price for the company. in a research report on Tuesday. Piper Jaffray Companies lifted their target price on Deciphera Pharmaceuticals to $50.00 and gave the company an “overweight” rating in a research report on Tuesday, June 12th. Zacks Investment Research raised Deciphera Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, June 11th. JPMorgan Chase & Co. lifted their target price on Deciphera Pharmaceuticals from $30.00 to $33.00 and gave the company an “overweight” rating in a research report on Monday, June 4th. Finally, BidaskClub downgraded Deciphera Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, May 14th. Four equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $47.57.

NASDAQ DCPH traded up $0.07 during trading on Tuesday, hitting $44.73. The stock had a trading volume of 8,399 shares, compared to its average volume of 488,033. The company has a market cap of $1.36 billion and a P/E ratio of -14.96. The company has a debt-to-equity ratio of 0.01, a current ratio of 11.12 and a quick ratio of 11.12. Deciphera Pharmaceuticals has a twelve month low of $15.15 and a twelve month high of $45.61.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last released its earnings results on Tuesday, May 8th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.04). analysts anticipate that Deciphera Pharmaceuticals will post -2.72 EPS for the current fiscal year.

Several institutional investors have recently made changes to their positions in the company. New York State Common Retirement Fund grew its position in shares of Deciphera Pharmaceuticals by 37.5% during the first quarter. New York State Common Retirement Fund now owns 9,900 shares of the company’s stock worth $198,000 after buying an additional 2,700 shares in the last quarter. American International Group Inc. acquired a new position in shares of Deciphera Pharmaceuticals during the fourth quarter worth about $126,000. Schwab Charles Investment Management Inc. grew its position in shares of Deciphera Pharmaceuticals by 20.4% during the first quarter. Schwab Charles Investment Management Inc. now owns 33,791 shares of the company’s stock worth $678,000 after buying an additional 5,737 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of Deciphera Pharmaceuticals during the first quarter worth about $152,000. Finally, The Manufacturers Life Insurance Company acquired a new position in shares of Deciphera Pharmaceuticals during the fourth quarter worth about $179,000. 47.68% of the stock is owned by institutional investors and hedge funds.

Deciphera Pharmaceuticals Company Profile

Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors.

The Fly

Analyst Recommendations for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply